Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGIO

AGIO - Agios Pharmaceuticals Inc Stock Price, Fair Value and News

32.26USD-0.06 (-0.19%)Market Closed
Watchlist

Market Summary

USD32.26-0.06
Market Closed
-0.19%

AGIO Alerts

  • 3 major insider sales recently.

AGIO Stock Price

View Fullscreen

AGIO RSI Chart

AGIO Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-5.16

Price/Sales (Trailing)

62.99

EV/EBITDA

-6.37

Price/Free Cashflow

-6.11

AGIO Price/Sales (Trailing)

AGIO Profitability

EBT Margin

-803.89%

Return on Equity

-43.41%

Return on Assets

-37.57%

Free Cashflow Yield

-16.36%

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

28.8M

Rev. Growth (Yr)

-18.85%

Rev. Growth (Qtr)

-31.19%

AGIO Earnings

Earnings (TTM)

-352.1M

Earnings Growth (Yr)

-362.66%

Earnings Growth (Qtr)

-5.05%

Breaking Down AGIO Revenue

Last 7 days

5.5%

Last 30 days

16.6%

Last 90 days

19.1%

Trailing 12 Months

-7.0%

How does AGIO drawdown profile look like?

AGIO Financial Health

Current Ratio

12.27

AGIO Investor Care

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

-6.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202319.7M26.1M30.0M28.8M
202200012.3M
20210000
2020174.8M184.3M193.7M203.2M
2019115.9M101.7M112.5M117.9M
201841.3M70.3M74.2M94.4M
201749.1M53.5M55.9M43.0M
201670.7M64.5M68.0M69.9M
201562.0M66.9M38.4M44.6M
201427.7M29.8M57.5M65.4M
201325.1M25.1M25.1M25.5M
201222.7M23.5M24.3M25.1M
201100021.8M

Tracking the Latest Insider Buys and Sells of Agios Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 26, 2024
schenkein david p
sold
-677,441
33.19
-20,411
-
Feb 26, 2024
schenkein david p
acquired
645,804
31.64
20,411
-
Feb 23, 2024
schenkein david p
sold
-1,577,510
33.05
-47,731
-
Feb 23, 2024
schenkein david p
acquired
1,510,210
31.64
47,731
-
Feb 20, 2024
washburn theodore james jr.
sold
-13,421
26.63
-504
principal accounting officer
Feb 14, 2024
gheuens sarah
sold
-16,139
25.14
-642
chief medical officer
Feb 14, 2024
burns james william
sold
-13,701
25.14
-545
chief legal officer
Feb 14, 2024
washburn theodore james jr.
sold
-6,863
25.14
-273
principal accounting officer
Feb 12, 2024
burns james william
acquired
-
-
1,833
chief legal officer
Feb 12, 2024
washburn theodore james jr.
acquired
-
-
777
principal accounting officer

1–10 of 50

Which funds bought or sold AGIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-71,245
614,875
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
2,319,000
2,319,000
0.20%
Feb 16, 2024
Aspect Partners, LLC
new
-
8,039
8,039
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-0.09
-4,066,000
36,181,000
-%
Feb 15, 2024
BARCLAYS PLC
added
27.87
453,000
3,446,000
-%
Feb 15, 2024
Virtus ETF Advisers LLC
added
18.72
19,963
312,582
0.20%
Feb 15, 2024
Legal & General Group Plc
added
1.79
-112,467
1,224,430
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
1,047
1,047
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
78.14
821,059
2,182,930
-%
Feb 14, 2024
EARNEST PARTNERS LLC
sold off
-100
-198
-
-%

1–10 of 43

Are Funds Buying or Selling AGIO?

Are funds buying AGIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGIO
No. of Funds

Unveiling Agios Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
6.31%
3,524,000
SC 13G/A
Feb 14, 2024
rock springs capital management lp
3.85%
2,152,173
SC 13G/A
Feb 13, 2024
bb biotech ag
7.2%
4e+06
SC 13G/A
Feb 12, 2024
vanguard group inc
10.02%
5,599,917
SC 13G/A
Feb 12, 2024
vanguard group inc
9.89%
5,527,438
SC 13G/A
Feb 08, 2024
farallon capital partners, l.p.
0.6%
350,343
SC 13G/A
Jan 25, 2024
blackrock inc.
8.9%
4,962,237
SC 13G/A
Jan 22, 2024
state street corp
4.70%
2,625,685
SC 13G/A
Nov 09, 2023
farallon capital partners, l.p.
0.6%
332,366
SC 13G
Nov 09, 2023
wellington management group llp
3.95%
2,200,757
SC 13G/A

Recent SEC filings of Agios Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 29, 2024
4
Insider Trading
Feb 27, 2024
144
Notice of Insider Sale Intent
Feb 27, 2024
4
Insider Trading
Feb 26, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
4
Insider Trading
Feb 15, 2024
10-K
Annual Report
Feb 15, 2024
8-K
Current Report
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading

Peers (Alternatives to Agios Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
35.3B
6.8B
-16.59% -47.80%
-7.48
5.15
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.0B
1.8B
-23.99% -31.71%
-43.22
10.41
76.23% 61.08%
16.3B
2.4B
-4.89% -18.90%
97.14
6.73
15.42% 18.43%
13.1B
3.7B
-7.62% -26.87%
21.93
3.55
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
-3.38% -9.50%
26.46
4.74
85.90% -14.05%
687.2M
983.7M
-9.17% -57.89%
-1.26
0.7
-50.36% 17.16%
201.6M
4.9M
-14.18% -58.18%
-1.22
41.23
-57.57% 50.48%
135.5M
881.7K
289.54% 381.25%
-2.86
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Agios Pharmaceuticals Inc News

Latest updates
AmericanBankingNEWS36 hours ago

Agios Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-31.2%5,091,0007,399,0008,254,0008,091,0006,273,5003,516,0001,793,000694,000475,000256,00014,852,33329,448,66744,045,0001,115,00044,106,50087,098,00035,440,00026,024,00026,221,00030,227,00030,013,000
Costs and Expenses4.7%113,380,000108,296,000100,412,00096,222,000103,482,00094,606,000103,222,000101,977,000104,827,00091,152,00091,222,00091,217,00085,332,00080,290,00083,264,00087,030,000-86,607,000135,084,000140,082,000127,710,000-
Operating Expenses------------------135,084,000140,082,000127,710,000126,369,000
  S&GA Expenses36.7%35,305,00025,822,00030,409,00028,367,00032,771,00029,123,00028,264,00031,515,00031,528,00027,152,00029,215,00033,550,00025,908,50028,347,00029,178,00031,672,0004,807,00033,019,00032,390,00031,791,00031,858,000
  R&D Expenses-5.3%77,489,00081,841,00068,895,00067,301,00070,298,00064,966,00074,523,00070,123,00073,299,00064,000,00062,007,00057,667,00059,423,50051,943,00054,086,00055,358,000-90,384,000101,672,000107,389,00095,585,00093,809,000
EBITDA Margin-4.1%-7.73-7.42-8.53-11.33-18.15-1.71-1.71-1.71-1.71-1.64-1.62-1.61---------
Income Taxes-100.0%-785,000801,000--1,940,00098,000-1,842,0007,162,0002,716,0006,200,000----------
Earnings Before Taxes----------98,584,000-84,259,000-82,790,000-90,877,000-84,541,000-79,175,000-81,495,000-84,094,000-----
EBT Margin-4.1%-8.04-7.72-8.87-11.78-18.88-1.75-1.75-1.75-1.75-1.69-1.66-1.65---------
Net Income-5.1%-95,940,000-91,324,000-83,806,000-81,018,00036,526,000-81,747,000-91,806,000-94,774,000-94,627,000-88,766,000-86,217,0001,874,325,000-97,657,000-98,979,000-90,478,000-40,256,000-102,350,000-106,173,000-109,871,000-93,078,000-91,794,000
Net Income Margin-66.9%-12.21-7.32-8.04-11.08-18.88-1.79-1.82-1.797.907.887.837.81---------
Free Cashflow-17.3%-72,722,000-62,012,000-66,745,000-95,582,000-66,276,000-71,389,000-76,155,000-100,539,000-88,595,000-85,162,000-117,543,000-121,761,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.0%9371,0071,0851,1511,2391,1801,2521,3361,4381,5411,8752,488853908976800891699784822858
  Current Assets18.4%8347047577928337858709751,0641,3051,7032,355637669846587612490534557614
    Cash Equivalents37.1%88.0064.0085.0010413912289.0080.002034009691,88812710529689.0081.0082.0084.0010371.00
  Inventory10.4%19.0017.0016.0011.008.005.004.002.00----15.0011.0011.0010.007.006.005.002.001.00
  Net PPE-8.4%15.0017.0020.0021.0023.0025.0027.0029.0029.0025.0027.0029.0031.0033.0034.0034.0031.0024.0023.0024.0024.00
Liabilities4.7%126120121115138130128128146147153192453428418174250250251202171
  Current Liabilities16.3%68.0058.0055.0045.0063.0054.0048.0046.0060.0058.0061.0097.0094.0070.0064.0070.0093.0092.0090.0081.0094.00
Shareholder's Equity-8.5%8118879641,0371,1011,0501,1241,2071,2921,3951,7222,297400480558625641448533620688
  Retained Earnings-13.2%-822-726-635-551-470-507-425-333-238-144-55.3731.00-1,843-1,745-1,646-1,556-1,516-1,413-1,307-1,197-1,104
  Additional Paid-In Capital0.6%2,4372,4222,4112,3992,3862,3752,3622,3512,3342,3222,3062,2662,2432,2262,2042,1822,1561,8621,8401,8181,794
Shares Outstanding0.1%56.0056.0056.0056.0055.0055.0055.0055.0054.0057.0065.0070.00---------
Float-------1,200---3,268---3,280---2,563--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-17.6%-72,488-61,643-66,748-95,183-66,163-71,351-74,229-97,735-84,093-85,184-117,294-120,749-49,397-68,207-67,797-105,358-93,611-85,589-88,151-103,271-74,187
  Share Based Compensation52.2%13,8149,07611,73710,13911,46511,15611,16515,51011,62112,14814,88514,85413,34114,97717,61415,6702,80718,58818,54718,10818,187
Cashflow From Investing142.8%95,51339,34147,12557,59682,951104,07082,813-26,573-94,419-232,731-298,1491,874,07771,396-126,24422,459108,135-184,77380,38164,480131,352-12,805
Cashflow From Financing-55.0%8471,8822372,46722.001,187-67.001,208-18,586-250,985-503,4587,2615823,448252,1035,385277,6063,3373,8084,8601,016
  Buy Backs---------19,048254,391-----------

AGIO Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenue$ 26,823$ 14,240$ 0
Operating expenses   
Cost of sales2,8811,7040
Research and development295,526279,910256,973
Selling, general and administrative119,903121,673121,445
Total operating expenses418,310403,287378,418
Loss from operations(391,487)(389,047)(378,418)
Gain on sale of contingent payments0127,8530
Royalty income from gain on sale of oncology business09,8516,639
Interest income, net33,34412,793836
Other income, net6,0556,74914,433
Net loss from continuing operations(352,088)(231,801)(356,510)
Net income from discontinued operations, net of tax001,961,225
Net (loss) income$ (352,088)$ (231,801)$ 1,604,715
Net loss from continuing operations per share - basic (in usd per share)$ (6.33)$ (4.23)$ (5.90)
Net loss from continuing operations per share - diluted (in usd per share)(6.33)(4.23)(5.90)
Net income from discontinued operations per share - basic (in usd per share)0032.45
Net income from discontinued operations per share - diluted (in usd per share)0032.45
Net (loss) income per share - basic (in usd per share)(6.33)(4.23)26.55
Net (loss) income per share - diluted (in usd share)$ (6.33)$ (4.23)$ 26.55
Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share – basic (in shares)55,651,48754,789,43560,447,346
Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share – diluted (in shares)55,651,48754,789,43560,447,346
Product revenue, net   
Revenues:   
Total revenue$ 26,823$ 11,740$ 0
Milestone revenue   
Revenues:   
Total revenue$ 0$ 2,500$ 0

AGIO Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 88,205$ 139,259
Marketable securities688,723643,860
Accounts receivable, net2,8102,206
Inventory19,0768,492
Prepaid expenses and other current assets35,02138,955
Total current assets833,835832,772
Marketable securities29,435313,874
Operating lease assets54,40965,129
Property and equipment, net15,38222,987
Other non-current assets4,0573,956
Total assets937,1181,238,718
Current liabilities:  
Accounts payable9,78018,616
Accrued expenses43,16730,350
Operating lease liabilities15,00813,663
Total current liabilities67,95562,629
Operating lease liabilities, net of current portion56,98871,996
Other non-current liabilities1,1563,279
Total liabilities126,099137,904
Commitments and contingent liabilities (Note 16)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 202200
Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 20227271
Additional paid-in capital2,436,5232,386,325
Accumulated other comprehensive loss(441)(12,535)
Accumulated deficit(822,649)(470,561)
Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022)(802,486)(802,486)
Total stockholders’ equity811,0191,100,814
Total liabilities and stockholders’ equity$ 937,118$ 1,238,718
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.agios.com
 EMPLOYEES389

Agios Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Agios Pharmaceuticals Inc? What does AGIO stand for in stocks?

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agios Pharmaceuticals Inc (AGIO)?

As of Thu Feb 29 2024, market cap of Agios Pharmaceuticals Inc is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers. The fair value of Agios Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agios Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agios Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

What is Agios Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AGIO's PE ratio (Price to Earnings) is -5.16 and Price to Sales (PS) ratio is 62.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agios Pharmaceuticals Inc's stock?

In the past 10 years, Agios Pharmaceuticals Inc has provided -0.019 (multiply by 100 for percentage) rate of return.